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Abstract
Antiplatelet therapy is a very important part of medical therapy for patients after 
acute coronary syndrome (ACS) as well as in a stable coronary artery disease (CAD). 
The use of antiplatelet therapy after coronary artery bypass graft surgery (CABG) 
still is a controversial theme in daily clinical practice. While guidelines referring to 
dual antiplatelet therapy (DAPT) after ACS with proceeding percutaneous coronary 
intervention (PCI) are uniform, there are doubts regarding DAPT after CABG, 
especially in setting of chronic coronary syndrome (CCS). Recommendations are 
mostly based on expert opinion and not on multiple randomized controlled trials 
(RCT) or meta-analyses. Resistance to aspirin (acetylsalicylic acid, ASA) or other 
antiplatelet drugs is known after CABG, and further RCTs are needed to assess the 
effect on clinical outcome as well as the role of DAPT after CABG.
Keywords: antiplatelet therapy, coronary artery bypass grafting (CABG),  
resistance to antiplatelet drugs, acute coronary syndrome (ACS),  
chronic coronary syndromes (CCS)
1. Introduction
An important and integral part of an optimal medicament therapy for patients 
with CAD in an acute as well as in a stable, chronic phase of the disease is anti-
platelet therapy. The estimated number of patients requiring DAPT, consisting 
of a combination of ASA and an oral inhibitor of the platelet P2Y12 receptor for 
adenosine 5′-diphosphate (ADP), is considerable and has increased over time all 
around the world. Based on population estimates from 2015, in Europe 1.4–2.2 
million patients per year may have an indication for DAPT after coronary interven-
tion or myocardial infarction (MI), respectively [1]. There is, however, confusion 
about the optimal type and duration of DAPT in patients with established CAD, 
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undergoing coronary revascularization or not. This derives from apparently 
conflicting results given in the available studies and limited evidence on vari-
ous patient subsets [1]. Depending on the disease stage (ACS with PCI, CCS 
or coronary surgical revascularization), and comorbidity of each patient (e.g., 
atrial fibrillation, left ventricular thrombus, etc.), the strategy of antiplatelet/
anticoagulant therapy is altered (combination of drugs, dosing, and duration of 
therapy). In patients with ACS treated with coronary stent implantation, DAPT is 
recommended for 12 months (preferring ticagrelor combined with ASA) [1]. In a 
patient with stable CAD treated with coronary stent implantation, DAPT consist-
ing of clopidogrel in addition to aspirin is recommended for 6 months irrespective 
of the stent type (Class I, level of evidence A), and DAPT up to 12 months may be 
reasonable (Class IIb, level of evidence A) [1]. If treated with drug-coated balloon, 
DAPT (aspirin plus clopidogrel) should be considered for 6 months (Class IIa, level 
of evidence B) and prolonged up to 12 months in tolerant patients without bleeding 
complications [1]. As opposite, guidelines and especially clinical practice are not 
uniform and specific regarding patients who will undergo CABG. Latest guidelines 
regarding DAPT after CABG give general recommendation for duration and choice 
of antiplatelet therapy with relatively strong class of recommendation I or IIa/IIb1. 
Still, level of evidence in recommendations is mostly C or B2 which points out that 
the foundation of recommendations is based on expert opinion and not on multiple 
RCTs or meta-analyses [1].
This chapter will give an overview of antiplatelet drugs, their mechanism of 
action, possible resistance to antiplatelet drugs, and clinical significance of resis-
tance to antiplatelet drugs. Also, it will give an overview of literature regarding 
duration and choice of antiplatelet therapy after CABG in setting of ACS or CCS.
2. Antiplatelet therapy
2.1 Aspirin
Aspirin (acetylsalicylic acid, ASA) is classified among the nonsteroidal anti-
inflammatory drugs (NSAIDs) and has analgesic, antipyretic, and antiplatelet 
properties. ASA achieves its effect primarily by interfering with the biosynthesis 
of cyclic prostanoids: thromboxane A2 (TXA2), prostacyclin, and other prosta-
glandins [2]. Low dose of ASA blocks the enzymatic effect of cyclooxygenase-1 
(COX-1) on the transformation of arachidonic acid into prostaglandin G2 and then 
into prostaglandin H2 which is modified by specific synthases, producing prosta-
glandins and TXA2, an important mediator of the platelet aggregation response and 
in vasoconstriction [2–4]. One of the earliest placebo-controlled RCTs of ASA in 
patients with ACS consisted of 1266 men with unstable angina, and the combined 
primary end point of death and nonfatal MI at 12 weeks was reduced by 50% in 
patients receiving ASA rather than placebo [5]. The Second International Study of 
Infarct Survival (ISIS-2) study involving patients administered with daily 160-mg 
ASA started within the first day of MI and continued for 5 weeks and showed a 
significant risk reduction in total vascular mortality (23%) as well as a similar risk 
reduction of from all-cause mortality [6, 7]. Therapy with ASA has become regular 
for all patients suspected of having an ACS [7, 8].
1 Class I, strong; Class IIa, moderate; Class IIb, weak; Class III, no benefit/harm.
2 A, multiple RCTs/meta-analyses; B, single RCTs/large observational studies; C, expert opinion/small 
studies.
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2.2 Clopidogrel
Clopidogrel is a second generation of thienopyridine antiplatelet agents and a 
P2RY12 inhibitor (purinergic receptor P2Y, G-protein coupled 12) which achieves 
its effect by irreversibly binding to the platelet P2RY12 receptor and blocking 
ADP-mediated platelet activation and aggregation [9]. It also inhibits collagen 
and thrombin-induced platelet aggregation which can be overcome by increased 
concentration of this agonist [10]. Clopidogrel versus aspirin in patients at risk of 
ischemic events (CAPRIE) trial demonstrated that long-term administration of 
clopidogrel to patients with atherosclerotic vascular disease is more effective than 
ASA in reducing the combined risk of ischemic stroke, MI, or vascular death, and 
the overall safety profile of clopidogrel is at least as good as that of medium-dose 
ASA [11]. The rate of reported gastrointestinal bleeding complication was signifi-
cantly lower in the clopidogrel group than in the ASA group, and no difference in 
intracerebral hemorrhage, hemorrhagic death, thrombocytopenia, or neutropenia 
was noted between the two groups [7, 12]. Clopidogrel was then in 1997 approved 
by Food and Drug Administration (FDA) for use in secondary prevention of 
cardiovascular disease [7].
2.3 Ticagrelor
Ticagrelor is an orally administered direct-acting P2Y12-receptor antagonist [13, 
14]. In vitro studies have demonstrated that ticagrelor binds reversibly and noncom-
petitively to the P2Y12 receptor at a site distinct from that of the endogenous agonist 
ADP [13]. In contrast, the thienopyridine compounds clopidogrel and prasugrel 
bind irreversibly to the P2Y12 receptor for the life of the platelet [15]. Ticagrelor was 
evaluated in patients with stable CAD in the Dose Confirmation Study Assessing 
Antiplatelet Effects of AZD6140 vs. Clopidogrel in Non–ST-Segment Elevation 
Myocardial Infarction (DISPERSE) trial [16]. In this randomized trial, patients with 
stable CAD who were taking ASA were administered either ticagrelor or clopido-
grel, and after trial findings, the formulation of ticagrelor was changed, and the 
new corresponding doses of 90 mg and 180 mg twice a day were targeted in future 
studies [16, 17]. In the ONSET/OFFSET trial, the pharmacodynamic response of 
ticagrelor was assessed in patients with stable CAD, and significantly greater inhibi-
tion of platelet activation has been achieved in patients treated with ticagrelor plus 
ASA than with clopidogrel plus ASA [18].
2.4 Prasugrel
Prasugrel is an irreversible antagonist of the platelet ADP P2Y12 receptor and 
characterized by more potent antiplatelet effects, lower interindividual variability 
in platelet response, and faster onset of activity than clopidogrel [19]. The TRITON-
TIMI 38 trial comparing prasugrel with clopidogrel in patients with moderate to 
high risk ACS (ST-elevation myocardial infarction, non-ST elevation myocardial 
infarction, and unstable angina) who underwent PCI demonstrated improved 
clinical outcomes with prasugrel as compared to clopidogrel [20]. A systematic 
review and recent meta-analysis suggest that prasugrel might have a better efficacy 
profile than ticagrelor in patients with ACS undergoing PCI, but this advantage was 
only seen in pooled observational studies and is likely to be affected by selection 
bias [21]. The latest trial comparing ticagrelor with prasugrel randomized 4018 
patients which presented with ACS with or without ST-segment elevation (in whom 
invasive evaluation was planned), and the incidence of death, MI, or stroke was 
significantly lower among those who received prasugrel than among those who 
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received ticagrelor, and the incidence of major bleeding was not significantly differ-
ent between the two groups [22]. On the other hand, in the observational analysis 
of STEMI patients who underwent primary PCI, ticagrelor was associated with 
improved outcomes compared with clopidogrel and prasugrel [23].
3. Resistance to antiplatelet therapy and its clinical significance
The success of CABG depends mainly on the patency of the graft vessels; 
vein graft patency and disease have been shown to be closely related to long-term 
survival after CABG [24]. Vein graft disease consists of three different but related 
pathological processes: thrombosis, intimal hyperplasia, and atherosclerosis, where 
early thrombosis is a major cause of vein graft friction during the first month after 
CABG, while later on intimal hyperplasia is the leading cause of graft disease [25, 
26]. Platelets participate in forming of blood clots, likewise they have an important 
role in graft thrombosis after CABG, and ASA is the primary antiplatelet drug that 
has been shown to improve vein graft patency within the first year after CABG 
[26–28]. Laboratory investigations showed that the expected inhibition of platelet 
function is not always achieved, which is called “aspirin nonresponse” or “aspirin 
resistance.”
Speaking about nonresponse and resistance to aspirin, there are two terms in 
use. The first one is aspirin treatment failure which is defined as the occurrence 
of occlusive cardiovascular disease events despite the regular intake of aspirin in 
recommended doses [29]. Platelets are activated by many different pathways, and 
there are many factors that contribute to thrombotic event in addition to platelet 
aggregation. Occurrence of an ischemic event or treatment failure during single 
antiplatelet therapy is not synonymous with antiplatelet resistance. The second 
term is aspirin resistance or nonresponsiveness, and it is a laboratory phenomenon; 
therefore persistent presence of COX-1 activity after treatment with aspirin is an 
indicator of aspirin resistance [29]. Antiplatelet resistance to aspirin is only mean-
ingful when it is highly associated with clinical outcomes. In a review article of anti-
platelet treatment after CABG, a summary of benefit and failure of aspirin therapy 
is given [26]. It is emphasized that in the early period after CABG, increased risk 
of bypass thrombosis (among others, due to platelet activation and endothelial cell 
disruption of the graft) occurs simultaneously with increased prevalence of aspirin 
resistance [26, 30]. The underlying mechanisms of aspirin resistance are uncertain 
and largely hypothetical, i.e., increased platelet turnover, enhanced platelet reactiv-
ity, systemic inflammation, and drug–drug interaction are discussed [26, 31, 32]. 
It is also important to differentiate transient aspirin resistance after surgery from 
permanent aspirin nonresponse due to genetic polymorphisms [33] or comorbidi-
ties, such as hypercholesterolemia or diabetes [26, 34].
In clinical practice, patient nonadherence is the most common cause of aspirin 
nonresponse or treatment failure. Genetic variability and the number of single 
nucleotide polymorphism (SNPs) have been reported as the cause of aspirin 
resistance based on laboratory testing, but there is no evidence for strong relation 
between genetic variability and aspirin resistance [35]. Enteric-coated aspirin and 
delayed absorption may result in an insufficient antithrombotic effect, especially 
in the acute setting (pseudoresistance) [36]. Two studies (case–control, retrospec-
tive) have suggested that the use of proton pump inhibitors increases platelet 
aggregation and the risk of thrombotic events, but randomized trials are needed 
[37, 38]. Treatment failure attributable to other causes than genetic variability or 
lack of adherence is common. Functional and biochemical evaluation of platelet 
aspirin resistance in patients undergoing CABG suggested that aspirin resistance 
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involves an impairment of both in vivo and in vitro inhibition of platelet functions 
and is probably due to a disturbed inhibition of platelet COX-1 by aspirin [39]. 
Aspirin resistance has been described in more than two-thirds of patients early 
after CABG [39, 40]. It has been shown that off-pump CABG (OPCABG) reduces 
platelet activation and turnover compared to on-pump CABG which may indicate 
that aspirin should be more effective after OPCABG [41], while other RCT showed 
no significant difference between off-pump and on-pump CABG in the rate of the 
30-day composite outcome, but at 1 year of follow-up, patients in the off-pump 
group had worse composite outcomes and poorer graft patency [42]. In a group 
of patients with OPCABG, aspirin resistance was observed in nearly 30% on day 
1 after OPCABG, but this is a transient phenomenon with only 4.5% of patients 
remaining so by postoperative day 10 [43]. The period of time passed after CABG 
is an important variable in measuring and analysis of the prevalence of aspirin 
resistance because results depend on it and vary from 10% up to >90% [26, 44, 45].
Regarding CABG, the number and size of trials investigating aspirin resistance 
with clinical endpoints are limited. A review of studies related to aspirin use after 
CABG suggested that clinical studies investigating the critical period early after 
CABG are necessary to correlate the results of reproducible assays with clinical 
outcomes that can possibly be improved by alterations in antiplatelet strategy [26]. 
The benefits and risks of ASA on thrombosis (BRAT) was the first prospective mul-
ticenter study with the objectives to determine the prevalence of aspirin responder 
or nonresponder status in patients undergoing CABG and to determine the clinical 
significance [46]. The 2-year follow-up period failed to show significant differences 
in thrombotic event rates (MI, unstable angina, cardiac death, or stroke) between 
aspirin responders and nonresponders [46]. In a setting of 225 patients undergoing 
elective OPCABG, aspirin resistance was defined by diagnostic findings on at least 
two of three separate assays (thromboelastography, whole blood aggregometry, and 
whole blood flow cytometry), and after multivariate logistic regression analysis, 
aspirin resistance on day 1 was retained as an independent predictor of vein graft 
thrombosis [47].
In the prospective randomized study to address the clinical impact of aug-
mented antiplatelet therapy after elective CABG in patients with aggregometry-
documented aspirin resistance, the addition of clopidogrel in patients found to 
be aspirin resistant after CABG did not reduce the incidence of adverse events, 
nor did it increase the number of recorded bleeding events [48]. A study on 60 
patients who went to elective OPCABG and were divided into two groups to receive 
mono-antiplatelet treatment (MAPT) with ASA or DAPT with ASA and clopidogrel 
has shown that clopidogrel in addition to ASA reduces the incidence of OPCABG-
related aspirin resistance, DAPT can be safely applied early after surgery, and there 
were no significant differences between two groups in postoperative bleeding [49]. 
A recent prospective, observational, bicentric cohort study indicated a high inci-
dence of perioperative ASA nonresponse in patients following CABG, and no effect 
on the incidence of cardiovascular events was recorded in the 1-year follow-up [50]. 
Similar was concluded in a small low-risk cohort patients in which reduced ASA 
responsiveness as assessed with impedance aggregometry was not associated with 
increased incidence of major adverse cardiac and thromboembolic events and mor-
tality after CABG surgery [51]. In a randomized trial on 68 patients, it was tested 
whether more frequent dosing improves ASA response following CABG surgery, 
and it was noted that twice-daily compared with once-daily dosing reduces ASA 
hyporesponsiveness after CABG surgery, but the efficacy of twice-daily ASA needs 
to be tested in a trial powered for clinical outcomes [52]. In comparison, meta-anal-
yses of studies consisting of patients with cardiovascular disease (not only CABG 
patients) suggested that patients who were resistant to aspirin were at a greater risk 
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of clinically important cardiovascular morbidity long term than patients who were 
sensitive to aspirin [53–55].
Concerning clopidogrel, patients with “high on-treatment platelet reactivity” 
(HPR) are divided into groups—nonresponsive, hyporesponsive, or resistant [56]. 
The term resistance or nonresponsiveness to an antiplatelet drug is used to describe 
a pharmacodynamics phenomenon where there is no clinically meaningful change 
in platelet function after treatment as compared with the baseline. In studies where 
light transmittance aggregometry was used, a change in maximal aggregation ≤10 
percent from baseline, using ADP as the agonist, is defined as “resistance” [56]. 
In a systematic review of literature on clinical importance of ASA and clopidogrel 
resistance, almost all included studies have suggested a positive association between 
the risk of cardiovascular events and laboratory antiplatelet nonresponsiveness, 
and it was concluded that specific treatment recommendations are not established 
for patients who exhibit HPR during aspirin/clopidogrel therapy or who have poor 
platelet inhibition by clopidogrel [57]. A meta-analysis provided evidence that 
P2Y12 G52T/C34T polymorphism is related to a poor response of clopidogrel in 
patients; also a lack of association between T744C polymorphism and clopidogrel 
resistance was found [58]. Clopidogrel response in patients undergoing CABG 
remains unknown due to the fact that ASA is the drug of first choice after CABG, 
and clopidogrel administration (in addition to ASA) is recommended mainly in 
patients with ACS. However, previous reports indicate that the clopidogrel resis-
tance rate in coronary stent patients varies between 5 and 56% [59]. Prospective, 
observational study on clopidogrel platelet reactivity in 859 patients who under-
went OPCABG demonstrates that high residual platelet reactivity after clopidogrel 
administration is strongly associated with 1-year major adverse cardiovascular 
events (MACE)-free survival, and incidence of late MACEs was significantly higher 
in the HPR group than in the low platelet reactivity group, as such routine measure-
ment of platelet reactivity and thorough monitoring of patients with HPR after 
OPCAB are suggested [60].
The latest review of literature on resistance to P2Y12 receptor antagonism in 
CAD showed that the prevalence of HPR is greater in patients treated with clopi-
dogrel (approximately 30%) than in patients on the more novel antiplatelet agents 
prasugrel (3–15%) and ticagrelor (0–3%) [61]. Although meta-analyses show 
an effect of adjusting standard clopidogrel treatment based on platelet function 
testing, personalized therapy is not recommended because no large-scale RCT 
have shown any clinical benefit [61]. Nevertheless, it should be noticed that the 
performed RCTs were underpowered to show any clinical effect, and personalized 
therapy is recommended neither for patients on prasugrel nor those on ticagrelor 
due to low occurrence of HPR on these respective drugs [61]. The pharmacody-
namic response of ticagrelor in clopidogrel nonresponders with stable CAD was 
assessed in an RCT: The response to ticagrelor in clopidogrel nonresponders and 
responders and effect of switching therapies (RESPOND) trial [62]. Inhibition of 
platelet function was significantly increased in clopidogrel nonresponders treated 
with ticagrelor compared with clopidogrel, and platelet aggregation decreased from 
59 to 35% in patients who switched from clopidogrel to ticagrelor [62]. Despite the 
low platelet reactivity for both agents, comparisons have shown that ticagrelor is 
the most potent platelet inhibitor and has the lowest prevalence of HPR [63, 64]. 
Prasugrel resistance or variability in response is not clearly defined and depends 
on the in vitro system use, prasugrel resistance has been reported to occur in very 
few cases, and the mechanism of prasugrel resistance is still under investigation 
[65]. Despite small studies that have shown a few prasugrel-resistant patients due to 
low inhibition of platelet aggregation, the clinical significance of this phenomenon 
remains uncertain [65].
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3.1 Platelet function tests for monitoring antiplatelet agent therapy
Platelet function testing is traditionally done to identify congenital and acquired 
platelet function defects. It is considered qualitative testing requiring interpreta-
tion in the context of patient condition. There exist multiple methods, each with its 
advantages and disadvantages.
Six major platelet function tests are most commonly used in the assessment of 
the prevalence of aspirin resistance in patients with stable CAD:
• Light transmission aggregometry (LTA) after stimulation arachidonic acid (AA)
• LTA after ADP stimulation
• Whole blood aggregometry
• PFA-100®
• VerifyNow Aspirin®
• Urinary 11-dehydro-thromboxane B2 concentrations that are measured [66]
4. CABG and antiplatelet therapy
CABG is an effective treatment for left main or multivessel ischemic heart dis-
ease, but long-term results are compromised by the development of saphenous vein 
graft (SVG) disease. ASA has always been a golden standard to prevent graft occlu-
sion and adverse cardiac events after CABG [67]. DAPT was assessed in previous 
trials, but there is no clear evidence regarding its utility after CABG for preserving 
graft patency and reducing adverse cardiac events, especially in patients with stable 
ischemic heart disease (SIDH), recently referred as CCS. In the next subsections, it 
will be given an overview of available literature about efficacy of DAPT in preserv-
ing graft patency in setting of SIDH and CCS.
4.1 Antiplatelet therapy after CABG in setting of ACS
DAPT using ASA with either clopidogrel or ticagrelor is a standard of care for 
patients after ACS whether they were treated with PCI or medicament therapy 
only, preferring ticagrelor over clopidogrel [1, 68–71]. Latest guidelines recommend 
use of DAPT 1 year after CABG for patients with ACS [1, 71], although available 
evidence is limited to small RCTs and meta-analyses are substudies of larger RTCs. 
However, the choice between ASA and which P2Y12 inhibitor to use remains unclear 
in CABG. Synergistic antithrombotic effect of clopidogrel with ASA after ACS 
was evaluated in Unstable Angina to Prevent Recurrent Events (CURE) trial [72, 
73]. Treatment with DAPT (ASA + clopidogrel) reduced the risk of the primary 
composite outcome—MI and recurrent ischemia, cerebrovascular event, and death 
from cardiovascular causes (MACCE), but the risk of major bleeding is increased 
among patients treated with clopidogrel [72]. The postoperative benefit with DAPT 
was analyzed in subgroup of CURE patients who underwent CABG and then were 
randomized to ASA and to ASA and clopidogrel. The benefits of DAPT with ASA and 
clopidogrel were consistent among groups undergoing CABG, PCI, or medical ther-
apy, although the impact of DAPT among CABG patients did not reach significance 
for the primary composite outcome [73]. In a nationwide Danish cohort of real-life 
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patients revascularized with CABG after MI, the benefit and efficacy of postopera-
tive clopidogrel treatment in reducing risk of death or recurrent MI were confirmed 
[74]. The Platelet Inhibition and Patient Outcomes (PLATO) trial randomized 
patients with ACS to DAPT with either ASA plus ticagrelor 90 mg twice daily or ASA 
plus clopidogrel 75 mg once daily [75]. The composite primary end point of death 
from vascular causes, MI, or stroke was significantly reduced in the ticagrelor group, 
and ticagrelor was associated with a higher rate of major bleeding (no statistical dif-
ference in overall major bleeding). In a subgroup of patients who underwent CABG, 
effect on the primary outcome at 1 year was again consistent but did not reach sig-
nificance. Cardiovascular mortality and all-cause mortality were significantly lower 
with ticagrelor, and there was no significant statistical benefit of ticagrelor related 
to MI and stroke [75]. DAPT with clopidogrel and ticagrelor in patients with non 
ST-elevation acute coronary syndrome (NSTE-ACS) was evaluated 3 months after 
off-pump CABG (only arterial grafts were used) in retrospective observational study, 
and there was no significant difference in overall survival or composite outcome of 
MACCE or major bleeding [76]. Prasugrel was compared with clopidogrel in patients 
with acute coronary syndrome RCT (TRITON-TIMI 38) where DAPT with ASA plus 
clopidogrel 75 mg daily or ASA plus prasugrel 10 mg daily was used [77]. Although 
major bleeding complications were significantly higher with prasugrel, the primary 
composite outcome of MACCE was significantly lower in prasugrel group, and 
all-cause mortality within 30 days in a subgroup of patients undergoing CABG was 
significantly reduced [77]. Meta-analysis of nine RCT that confirms benefit of DAPT 
among the subset of patients after ACS who had undergone CABG suggests that 
higher-intensity (prasugrel or ticagrelor) than lower-intensity (clopidogrel) DAPT is 
associated with an approximate 50% lower all-cause mortality in such patients, but 
data are primarily based on post-randomization subset from a single RCT [78]. Latest 
review on DAPT and CABG with focus on ACS supports the use of DAPT with ASA 
and ticagrelor for patients with ACS after CABG [79].
4.2 Antiplatelet therapy after CABG in setting of CCS
Stable ischemic heart disease (SIHD) refers to patients with known or sus-
pected ischemic heart disease, including those with new-onset chest pain and 
those who have undergone PCI or CABG, and this term is used in 2014 ACC/AHA/
AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and 
Management of Patients With Stable Ischemic Heart Disease [80]. However, the 
disease is chronic, most often progressive and serious, even in clinically apparently 
silent periods. The new 2019 ESC Guidelines for the diagnosis and management 
of chronic coronary syndromes (CCS) emphasize that the dynamic nature of the 
CAD process results in various clinical presentations, which can be conveniently 
categorized as either ACS or CCS [81]. Latest guidelines note limited evidence on 
the role of DAPT after CABG in SIHD [1, 71]. 2016 ACC/AHA DAPT guideline 
update provides a class IIb recommendation for 12 months of DAPT to improve SVG 
patency [71]. The 2017 ESC focused update guideline suggests insufficient evidence 
to generally recommend DAPT postoperatively to reduce vein graft occlusion in 
stable patients who underwent CABG, unless concomitant or prior indication 
overrides [1]. Several studies have provided conflicting results on the effects of 
DAPT on the SVG patency. Graft patency was assessed with invasive coronary 
angiography or computerized tomography (CT). In Clopidogrel After Surgery for 
Coronary Artery disease (CASCADE) randomized trial, the combination of aspirin 
plus clopidogrel did not significantly reduce the process of SVG intimal hyperplasia 
(assessed with coronary angiography and intravascular ultrasound, IVUS) com-
pared with ASA monotherapy [82]. Graft patency was not significantly improved 
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in ROOBY trial [83] and a trial that randomized 100 patients after CABG [84]. In 
secondary analysis of CASCADE, the superiority of DAPT over ASA monotherapy 
in reducing the incidence of new occlusions within native coronary arteries after 
CABG was demonstrated [85]. Contradictorily, in Prevention of Coronary Artery 
Bypass Occlusion After Off-Pump Procedure (CRYSSA) trial, DAPT with ASA and 
clopidogrel was associated with significantly lower SVG occlusion rates than ASA 
monotherapy [86], and similar was shown in a previous RCT but with no significant 
differences in MACCE [87]. Observational studies in the cardiac surgery literature 
have suggested that clopidogrel may improve postoperative outcomes [88] and 
also demonstrated that the addition of clopidogrel to ASA was associated with a 
trend toward improved SVG patency 6 months after surgery [89], and it noted that 
postoperative clopidogrel was associated with less symptom recurrence and fewer 
adverse cardiac events [90]. Meta-analysis of DAPT with clopidogrel and ASA over 
monotherapy with ASA established that DAPT reduces the risk of SVG occlusion 
[91, 92] and was associated with a smaller incidence of early mortality but also 
linked with major bleeding episodes in the early postoperative period [92]. There is 
lack of studies that compare the effect of ticagrelor or prasugrel in addition to ASA 
on SVG patency. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone 
on SVG patency 1 year after elective CABG was assessed in RCT and demonstrated 
that DAPT with ticagrelor and aspirin significantly improved graft patency, but 
there was no significant improvement with ticagrelor alone or aspirin alone, no 
statistically significant difference in event rates of MACCE, and no major bleeding 
in DAPT group [93]. And most recently, the Ticagrelor Compared with Aspirin 
for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass 
Grafting (TiCAB) trial randomized patients in either ticagrelor twice daily or aspi-
rin once daily group (study did not evaluate DAPT), and the primary outcome of 
MACE at 12 months did not differ significantly between two groups [94]. In latest 
meta-analyses data were also contradictory. One meta-analysis showed that DAPT 
appears to be associated with a reduction in graft occlusion and major adverse car-
diac events in all-cause mortality, without significantly increasing major bleeding 
[95]. Improved graft patency with DAPT compared with aspirin was also shown in a 
meta-analysis of RCTs only [96]. Combined meta-analysis among patients undergo-
ing CABG suggested association of DAPT with lover cardiovascular mortality in 
observational studies, but such findings were not replicated in RCTs [97].
4.3  Triple therapy (aspirin, P2Y12 inhibitor, and OAC) in patients after PCI or 
CABG
Addition of DAPT to oral anticoagulant (OAC) therapy increases bleeding 
complications for two- to threefolds [98, 99]. Therefore, patients who need triple 
therapy (comorbidity such as atrial fibrillation, thrombus in left ventricle, deep 
venous thrombosis, mechanical heart valve) are at high risk of bleeding. Assessing 
ischemic and bleeding risks using validated risk predictors (e.g., CHA2DS2-VASc
3, 
ABC4, HAS-BLED5) with a focus on modifiable risk factors is one of the strategies to 
avoid bleeding complications. Triple therapy in patients undergoing PCI should last 
as short as possible (1 month if concerns about bleeding risks are prevailing and up 
3 CHA2DS2-VASc indicates congestive heart failure, hypertension, age ≥75  years (doubled), diabetes 
mellitus, prior stroke or transient ischemic attack or thromboembolism (doubled), vascular disease, age 
65–74 years, and sex category.
4 Age, biomarkers (GDF-15, cTnT-hs, hemoglobin), and clinical history (ABC).
5 Hypertension, abnormal renal and liver function, stroke, bleeding, labile INR, elderly, drugs or alcohol 
(HAS-BLED).
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to 6 months if concerns about ischemic risks are prevailing), and then dual therapy 
is to be considered (OAC and clopidogrel) up to 12 months [1]. Non-vitamin K oral 
anticoagulant (NOAC) should be considered instead of vitamin K antagonist (VKA). 
International normalized ratio (INR) is suggested to be in the lower part of the 
recommended target range, and time in therapeutic range should be maximized (i.e., 
>65–70%) when VKA is used [1, 71]. Using low dose (≤100 mg) of ASA is recom-
mended and also routine use of proton pump inhibitors (PPIs) [1, 71]. Clopidogrel 
is the P2Y12 inhibitor of choice in such regimen of therapy; the use of prasugrel and 
ticagrelor should be avoided [1]. In a study of 377 patients who underwent drug-elut-
ing stent implantation and had an indication for oral anticoagulation, prasugrel was 
evaluated as alternative to clopidogrel, and results showed an increased risk of bleed-
ing in patients needing triple therapy [100]. Recent meta-analysis demonstrated that 
the use of ticagrelor as part of dual or triple therapy is associated with significantly 
higher rates of clinically relevant hemorrhagic complications than clopidogrel [101]. 
Latest review article on this subject points out already known stronger antiplatelet 
effect of ticagrelor and prasugrel, yet they are not used because of the increased risk, 
whether real or perceived, which has not been confirmed with large RCT in patients 
with ACS and atrial fibrillation [102]. In patients eligible for CABG surgery, DAPT 
should be avoided on the top of OAC and is not suggested in which antiplatelet agent 
in addition to OAC should be used [1].
5. Conclusion
• There is no strong evidence based on RCTs or meta-analysis regarding duration 
and choice of antiplatelet agents after CABG, especially in setting of stable CAD.
• The 2017 ESC focused update guideline suggests insufficient evidence to 
generally recommend DAPT postoperatively to reduce graft occlusion in 
stable patients who underwent CABG, unless concomitant or prior indica-
tion overrides. In setting of ACS, combination of ASA with P2Y12 inhibitor is 
recommended up to 12 months after CABG, but the choice between ASA and 
which P2Y12 inhibitor to use is not clearly defined. In patients perceived at 
high ischemic risk with prior MI and CABG who have tolerated DAPT without 
bleeding complications, treatment with DAPT for longer than 12 months and 
up to 36 months may be considered [1].
• There is no clear evidence of aspirin resistance in CABG patients and effect 
on their clinical outcome. Also, there is no uniform data regarding addition 
of clopidogrel to ASA in reducing the incidence of CABG-related aspirin 
resistance.
• Available data suggests that the incidence of late MACEs was higher in the HPR 
group after clopidogrel administration post CABG, and also higher prevalence 
of HPR was shown in CAD patients treated with clopidogrel than patients 
treated with ticagrelor or prasugrel. Positive effect of adjusting standard 
clopidogrel treatment based on platelet function testing was shown; however, 
personalized therapy is not recommended because no large RCT demonstrated 
any clinical benefit.
• Ticagrelor and prasugrel have a low occurrence of HPR, and platelet function 
testing is not recommended; in addition there are no large RCT studies avail-
able on this subject.
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• Resistance to antiplatelet drugs and its impact to the clinical outcomes (bypass 
patency, major adverse cardiovascular events such as MI, PCI, re-do CABG, 
and cardiac mortality) of patients requires further investigation with larger 
studies.
• It is reasonable to assume (and meta-analyses of studies consisting of patients 
with cardiovascular disease suggest) that patients who are resistant to ASA 
have a greater risk of clinically important cardiovascular morbidity long term 
than ASA-sensitive patients.
• Further studies are needed in order to define the role of more aggressive 
antiplatelet therapy post CABG on graft patency and clinical outcome.
• Besides optimal antiplatelet therapy, other variables such as surgeon experi-
ence and skill, stage and severity of CAD, long-lasting postoperative control 
of cardiovascular risk factors, the degree of reduction of systolic function of 
left ventricle before CABG, and other associated comorbidity (e.g., diabetes, 
chronic renal failure, etc.) have to be taken into consideration when interpret-
ing MACCE and CABG patient outcomes.
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